{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T22:41:28Z","timestamp":1781649688501,"version":"3.54.5"},"reference-count":61,"publisher":"Spandidos Publications","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Mol Med Report"],"DOI":"10.3892\/mmr.2019.10810","type":"journal-article","created":{"date-parts":[[2019,11,11]],"date-time":"2019-11-11T12:47:58Z","timestamp":1573476478000},"source":"Crossref","is-referenced-by-count":5,"title":["Inhibition of CYP1B1 ameliorates cardiac hypertrophy induced by uremic toxin"],"prefix":"10.3892","author":[{"given":"Ying","family":"Zhang","sequence":"first","affiliation":[{"name":"Department of Nephrology, The Key Laboratory for The Prevention and Treatment of Chronic Kidney Disease of Chongqing, Kidney Center of PLA, Xinqiao Hospital, Army Medical University (Third Military Medical University), Chongqing 400037, P.R. China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shaobo","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of Nephrology, The Key Laboratory for The Prevention and Treatment of Chronic Kidney Disease of Chongqing, Kidney Center of PLA, Xinqiao Hospital, Army Medical University (Third Military Medical University), Chongqing 400037, P.R. China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yinghui","family":"Huang","sequence":"additional","affiliation":[{"name":"Department of Nephrology, The Key Laboratory for The Prevention and Treatment of Chronic Kidney Disease of Chongqing, Kidney Center of PLA, Xinqiao Hospital, Army Medical University (Third Military Medical University), Chongqing 400037, P.R. China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ke","family":"Yang","sequence":"additional","affiliation":[{"name":"Department of Nephrology, The Key Laboratory for The Prevention and Treatment of Chronic Kidney Disease of Chongqing, Kidney Center of PLA, Xinqiao Hospital, Army Medical University (Third Military Medical University), Chongqing 400037, P.R. China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yong","family":"Liu","sequence":"additional","affiliation":[{"name":"Department of Nephrology, The Key Laboratory for The Prevention and Treatment of Chronic Kidney Disease of Chongqing, Kidney Center of PLA, Xinqiao Hospital, Army Medical University (Third Military Medical University), Chongqing 400037, P.R. China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xianjin","family":"Bi","sequence":"additional","affiliation":[{"name":"Department of Nephrology, The Key Laboratory for The Prevention and Treatment of Chronic Kidney Disease of Chongqing, Kidney Center of PLA, Xinqiao Hospital, Army Medical University (Third Military Medical University), Chongqing 400037, P.R. China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chi","family":"Liu","sequence":"additional","affiliation":[{"name":"Department of Nephrology, The Key Laboratory for The Prevention and Treatment of Chronic Kidney Disease of Chongqing, Kidney Center of PLA, Xinqiao Hospital, Army Medical University (Third Military Medical University), Chongqing 400037, P.R. China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiachuan","family":"Xiong","sequence":"additional","affiliation":[{"name":"Department of Nephrology, The Key Laboratory for The Prevention and Treatment of Chronic Kidney Disease of Chongqing, Kidney Center of PLA, Xinqiao Hospital, Army Medical University (Third Military Medical University), Chongqing 400037, P.R. China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bo","family":"Zhang","sequence":"additional","affiliation":[{"name":"Department of Nephrology, The Key Laboratory for The Prevention and Treatment of Chronic Kidney Disease of Chongqing, Kidney Center of PLA, Xinqiao Hospital, Army Medical University (Third Military Medical University), Chongqing 400037, P.R. China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jinghong","family":"Zhao","sequence":"additional","affiliation":[{"name":"Department of Nephrology, The Key Laboratory for The Prevention and Treatment of Chronic Kidney Disease of Chongqing, Kidney Center of PLA, Xinqiao Hospital, Army Medical University (Third Military Medical University), Chongqing 400037, P.R. China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ling","family":"Nie","sequence":"additional","affiliation":[{"name":"Department of Nephrology, The Key Laboratory for The Prevention and Treatment of Chronic Kidney Disease of Chongqing, Kidney Center of PLA, Xinqiao Hospital, Army Medical University (Third Military Medical University), Chongqing 400037, P.R. China"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"2249","published-online":{"date-parts":[[2019,11,11]]},"reference":[{"key":"key20200713234411_b1-mmr-21-01-0393","doi-asserted-by":"publisher","first-page":"1388","DOI":"10.1159\/000492953","article-title":"Prognostic cardiovascular markers in chronic kidney disease","volume":"43","author":"Chen","year":"2018","journal-title":"Kidney Blood Press Res"},{"key":"key20200713234411_b2-mmr-21-01-0393","doi-asserted-by":"publisher","first-page":"R521","DOI":"10.1152\/ajpregu.00218.2017","article-title":"Risk of cardiovascular disease, end-stage renal disease, and stroke in postpartum women and their fetuses after a hypertensive pregnancy","volume":"315","author":"Cunningham","year":"2018","journal-title":"Am J Physiol Regul Integr Comp Physiol"},{"key":"key20200713234411_b3-mmr-21-01-0393","doi-asserted-by":"publisher","first-page":"571","DOI":"10.1080\/17512433.2018.1479252","article-title":"The impact of chronic kidney disease on medication choice and pharmacologic management in patients with heart failure","volume":"11","author":"Shah","year":"2018","journal-title":"Expert Rev Clin Pharmacol"},{"key":"key20200713234411_b4-mmr-21-01-0393","doi-asserted-by":"publisher","first-page":"800","DOI":"10.1038\/ki.2008.690","article-title":"Uremic cardiac hypertrophy is reversed by rapamycin but not by lowering of blood pressure","volume":"75","author":"Siedlecki","year":"2009","journal-title":"Kidney Int"},{"key":"key20200713234411_b5-mmr-21-01-0393","doi-asserted-by":"publisher","first-page":"298","DOI":"10.1016\/j.semnephrol.2018.02.009","article-title":"Cardiovascular disease risk in children with kidney disease","volume":"38","author":"Sethna","year":"2018","journal-title":"Semin Nephrol"},{"key":"key20200713234411_b6-mmr-21-01-0393","doi-asserted-by":"publisher","first-page":"231","DOI":"10.3346\/jkms.2017.32.2.231","article-title":"Baseline cardiovascular characteristics of adult patients with chronic kidney disease from the korean cohort study for outcomes in patients with chronic kidney disease (KNOW-CKD)","volume":"32","author":"Kim","year":"2017","journal-title":"J Korean Med Sci"},{"key":"key20200713234411_b7-mmr-21-01-0393","doi-asserted-by":"publisher","first-page":"1302","DOI":"10.2215\/CJN.00070109","article-title":"Chronic Renal Insufficiency Cohort (CRIC) Study: Baseline characteristics and associations with kidney function","volume":"4","author":"Lash","year":"2009","journal-title":"Clin J Am Soc Nephrol"},{"key":"key20200713234411_b8-mmr-21-01-0393","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1016\/j.lfs.2017.07.027","article-title":"Role of uremic toxin indoxyl sulfate in the progression of cardiovascular disease","volume":"185","author":"Gao","year":"2017","journal-title":"Life Sci"},{"key":"key20200713234411_b9-mmr-21-01-0393","doi-asserted-by":"publisher","first-page":"2434","DOI":"10.1681\/ASN.2014060543","article-title":"Klotho protects against indoxyl sulphate-induced myocardial hypertrophy","volume":"26","author":"Yang","year":"2015","journal-title":"J Am Soc Nephrol"},{"key":"key20200713234411_b10-mmr-21-01-0393","doi-asserted-by":"publisher","first-page":"110","DOI":"10.1016\/j.toxlet.2015.01.021","article-title":"Indoxyl sulfate induces oxidative stress and hypertrophy in cardiomyocytes by inhibiting the AMPK\/UCP2 signaling pathway","volume":"234","author":"Yang","year":"2015","journal-title":"Toxicol Lett"},{"key":"key20200713234411_b11-mmr-21-01-0393","doi-asserted-by":"publisher","first-page":"248","DOI":"10.1016\/j.atherosclerosis.2015.09.019","article-title":"Deleterious vascular effects of indoxyl sulfate and reversal by oral adsorbent AST-120","volume":"243","author":"Six","year":"2015","journal-title":"Atherosclerosis"},{"key":"key20200713234411_b12-mmr-21-01-0393","doi-asserted-by":"publisher","first-page":"1069","DOI":"10.1007\/s10157-018-1577-z","article-title":"Oral adsorbent AST-120 ameliorates gut environment and protects against the progression of renal impairment in CKD rats","volume":"22","author":"Yoshifuji","year":"2018","journal-title":"Clin Exp Nephrol"},{"key":"key20200713234411_b13-mmr-21-01-0393","doi-asserted-by":"publisher","first-page":"624","DOI":"10.5604\/01.3001.0010.3843","article-title":"Aryl hydrocarbon receptor (AhR) and its endogenous agonist-indoxyl sulfate in chronic kidney disease","volume":"71","author":"Kami\u0144ski","year":"2017","journal-title":"Postepy Hig Med Dosw (Online)"},{"key":"key20200713234411_b14-mmr-21-01-0393","doi-asserted-by":"publisher","first-page":"12383","DOI":"10.1074\/jbc.R116.767723","article-title":"Control of immune-mediated pathology via the aryl hydrocarbon receptor","volume":"292","author":"Wheeler","year":"2017","journal-title":"J Biol Chem"},{"key":"key20200713234411_b15-mmr-21-01-0393","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1186\/s12943-017-0636-5","article-title":"Aryl hydrocarbon receptor\/cytochrome P450 1A1 pathway mediates breast cancer stem cells expansion through PTEN inhibition and \u03b2-Catenin and Akt activation","volume":"16","author":"Al-Dhfyan","year":"2017","journal-title":"Mol Cancer"},{"key":"key20200713234411_b16-mmr-21-01-0393","doi-asserted-by":"publisher","first-page":"411","DOI":"10.1080\/03602530600632063","article-title":"The role of aryl hydrocarbon receptor in the pathogenesis of cardiovascular diseases","volume":"38","author":"Korashy","year":"2006","journal-title":"Drug Metab Rev"},{"key":"key20200713234411_b17-mmr-21-01-0393","doi-asserted-by":"publisher","first-page":"1278","DOI":"10.1021\/acs.molpharmaceut.5b00873","article-title":"Repurposing resveratrol and Fluconazole to modulate human cytochrome P450-mediated arachidonic acid metabolism","volume":"13","author":"El-Sherbeni","year":"2016","journal-title":"Mol Pharm"},{"key":"key20200713234411_b18-mmr-21-01-0393","doi-asserted-by":"publisher","first-page":"1461","DOI":"10.1161\/HYPERTENSIONAHA.110.150029","article-title":"Angiotensin II-induced vascular smooth muscle cell migration and growth are mediated by cytochrome P450 1B1-dependent superoxide generation","volume":"55","author":"Yaghini","year":"2010","journal-title":"Hypertension"},{"key":"key20200713234411_b19-mmr-21-01-0393","doi-asserted-by":"publisher","first-page":"1794","DOI":"10.1111\/bph.12066","article-title":"Soluble epoxide hydrolase inhibitor, TUPS, protects against isoprenaline-induced cardiac hypertrophy","volume":"168","author":"Althurwi","year":"2013","journal-title":"Br J Pharmacol"},{"key":"key20200713234411_b20-mmr-21-01-0393","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1097\/FJC.0000000000000494","article-title":"Inhibition of Mid-chain HETEs protects against angiotensin II-induced cardiac hypertrophy","volume":"70","author":"Elkhatali","year":"2017","journal-title":"J Cardiovasc Pharmacol"},{"key":"key20200713234411_b21-mmr-21-01-0393","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1007\/s11010-017-2943-y","article-title":"The role of cytochrome P450 1B1 and its associated mid-chain hydroxyeicosatetraenoic acid metabolites in the development of cardiac hypertrophy induced by isoproterenol","volume":"429","author":"Maayah","year":"2017","journal-title":"Mol Cell Biochem"},{"key":"key20200713234411_b22-mmr-21-01-0393","doi-asserted-by":"publisher","first-page":"733","DOI":"10.1038\/ki.2013.133","article-title":"Indolic uremic solutes increase tissue factor production in endothelial cells by the aryl hydrocarbon receptor pathway","volume":"84","author":"Gondouin","year":"2013","journal-title":"Kidney Int"},{"key":"key20200713234411_b23-mmr-21-01-0393","doi-asserted-by":"publisher","first-page":"402","DOI":"10.1006\/meth.2001.1262","article-title":"Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) method","volume":"25","author":"Livak","year":"2001","journal-title":"Methods"},{"key":"key20200713234411_b24-mmr-21-01-0393","doi-asserted-by":"publisher","first-page":"963","DOI":"10.1007\/s13277-015-3879-z","article-title":"Knockdown of Rad9A enhanced DNA damage induced by trichostatin A in esophageal cancer cells","volume":"37","author":"Pang","year":"2016","journal-title":"Tumour Biol"},{"key":"key20200713234411_b25-mmr-21-01-0393","doi-asserted-by":"publisher","first-page":"3933","DOI":"10.3390\/toxins7103933","article-title":"Exploring protein binding of uremic toxins in patients with different stages of chronic kidney disease and during hemodialysis","volume":"7","author":"Deltombe","year":"2015","journal-title":"Toxins (Basel)"},{"key":"key20200713234411_b26-mmr-21-01-0393","doi-asserted-by":"publisher","first-page":"e76778","DOI":"10.1371\/journal.pone.0076778","article-title":"The uremic toxin indoxyl sulphate enhances macrophage response to LPS","volume":"8","author":"Adesso","year":"2013","journal-title":"PLoS One"},{"key":"key20200713234411_b27-mmr-21-01-0393","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1007\/s10557-014-6510-4","article-title":"Cytochrome P450 1B1 contributes to increased blood pressure and cardiovascular and renal dysfunction in spontaneously hypertensive rats","volume":"28","author":"Jennings","year":"2014","journal-title":"Cardiovasc Drugs Ther"},{"key":"key20200713234411_b28-mmr-21-01-0393","doi-asserted-by":"publisher","first-page":"134","DOI":"10.1161\/HYPERTENSIONAHA.114.03275","article-title":"Estrogen metabolism by cytochrome P450 1B1 modulates the hypertensive effect of angiotensin II in female mice","volume":"64","author":"Jennings","year":"2014","journal-title":"Hypertension"},{"key":"key20200713234411_b29-mmr-21-01-0393","doi-asserted-by":"publisher","first-page":"916","DOI":"10.1161\/HYPERTENSIONAHA.115.06936","article-title":"6\u03b2-hydroxytestosterone, a cytochrome P450 1B1-testosterone-metabolite, mediates angiotensin II-induced renal dysfunction in male mice","volume":"67","author":"Pingili","year":"2016","journal-title":"Hypertension"},{"key":"key20200713234411_b30-mmr-21-01-0393","doi-asserted-by":"publisher","first-page":"F408","DOI":"10.1152\/ajprenal.00542.2011","article-title":"Involvement of cytochrome P-450 1B1 in renal dysfunction, injury, and inflammation associated with angiotensin II-induced hypertension in rats","volume":"302","author":"Jennings","year":"2012","journal-title":"Am J Physiol Renal Physiol"},{"key":"key20200713234411_b31-mmr-21-01-0393","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1016\/j.pharmthera.2017.03.007","article-title":"Potential role of CYP1B1 in the development and treatment of metabolic diseases","volume":"178","author":"Li","year":"2017","journal-title":"Pharmacol Ther"},{"key":"key20200713234411_b32-mmr-21-01-0393","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.ctrv.2017.10.013","article-title":"Cancer chemoprevention revisited: Cytochrome P450 family 1B1 as a target in the tumor and the microenvironment","volume":"63","author":"D'Uva","year":"2018","journal-title":"Cancer Treat Rev"},{"key":"key20200713234411_b33-mmr-21-01-0393","doi-asserted-by":"publisher","first-page":"539","DOI":"10.2217\/pgs-2018-0197","article-title":"A genetic polymorphism in the CYP1B1 gene in patients with squamous cell carcinoma of the esophagus: An Iranian Mashhad cohort study recruited over 10 years","volume":"19","author":"Moghadam","year":"2018","journal-title":"Pharmacogenomics"},{"key":"key20200713234411_b34-mmr-21-01-0393","doi-asserted-by":"publisher","first-page":"269","DOI":"10.7150\/jca.21774","article-title":"A single nucleotide polymorphism in CYP1B1 leads to differential prostate cancer risk and telomere length","volume":"9","author":"Gu","year":"2018","journal-title":"J Cancer"},{"key":"key20200713234411_b35-mmr-21-01-0393","doi-asserted-by":"publisher","first-page":"363","DOI":"10.1016\/j.vph.2013.02.004","article-title":"Cytochrome P450 epoxygenase metabolite, 14,15-EET, protects against soproterenol-induced cellular hypertrophy in H9c2 rat cell line","volume":"58","author":"Tse","year":"2013","journal-title":"Vasc Pharmacol"},{"key":"key20200713234411_b36-mmr-21-01-0393","doi-asserted-by":"publisher","first-page":"1537","DOI":"10.1096\/fj.02-0138com","article-title":"Testosterone, cytochrome P450, and cardiac hypertrophy","volume":"16","author":"Thum","year":"2002","journal-title":"FASEB J"},{"key":"key20200713234411_b37-mmr-21-01-0393","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1007\/s00204-015-1620-8","article-title":"The role of mid-chain hydroxyeicosatetraenoic acids in the pathogenesis of hypertension and cardiac hypertrophy","volume":"90","author":"Maayah","year":"2016","journal-title":"Arch Toxicol"},{"key":"key20200713234411_b38-mmr-21-01-0393","doi-asserted-by":"publisher","first-page":"625","DOI":"10.1016\/j.ekir.2018.01.002","article-title":"Risk Factors for Prognosis in Patients With Severely Decreased GFR","volume":"3","author":"Evans","year":"2018","journal-title":"Kidney Int Rep"},{"key":"key20200713234411_b39-mmr-21-01-0393","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1016\/j.toxlet.2019.03.002","article-title":"Molecular mechanisms of protein-bound uremic toxin-mediated cardiac, renal and vascular effects: Underpinning intracellular targets for cardiorenal syndrome therapy","volume":"308","author":"Savira","year":"2019","journal-title":"Toxicol Lett"},{"key":"key20200713234411_b40-mmr-21-01-0393","doi-asserted-by":"publisher","first-page":"H1","DOI":"10.1152\/ajpheart.00787.2016","article-title":"Vasculopathy in the setting of cardiorenal syndrome: Roles of protein-bound uremic toxins","volume":"313","author":"Guo","year":"2017","journal-title":"Am J Physiol Heart Circ Physiol"},{"key":"key20200713234411_b41-mmr-21-01-0393","first-page":"1","article-title":"Uremic toxicity of indoxyl sulfate","volume":"72","author":"Niwa","year":"2010","journal-title":"Nagoya J Med Sci"},{"key":"key20200713234411_b42-mmr-21-01-0393","doi-asserted-by":"publisher","first-page":"1551","DOI":"10.2215\/CJN.03980609","article-title":"European Uremic Toxin Work Group (EUTox): Serum indoxyl sulfate is associated with vascular disease and mortality in chronic kidney disease patients","volume":"4","author":"Barreto","year":"2009","journal-title":"Clin J Am Soc Nephrol"},{"key":"key20200713234411_b43-mmr-21-01-0393","doi-asserted-by":"publisher","first-page":"1771","DOI":"10.1093\/eurheartj\/ehp574","article-title":"Does indoxyl sulfate, a uraemic toxin, have direct effects on cardiac fibroblasts and myocytes?","volume":"31","author":"Lekawanvijit","year":"2010","journal-title":"Eur Heart J"},{"key":"key20200713234411_b44-mmr-21-01-0393","doi-asserted-by":"publisher","first-page":"2089","DOI":"10.1093\/ndt\/gfp007","article-title":"Oral charcoal adsorbent (AST-120) prevents progression of cardiac damage in chronic kidney disease through suppression of oxidative stress","volume":"24","author":"Fujii","year":"2009","journal-title":"Nephrol Dial Transplant"},{"key":"key20200713234411_b45-mmr-21-01-0393","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1159\/000476074","article-title":"Aryl hydrocarbon receptor activation in chronic kidney disease: Role of Uremic Toxins","volume":"137","author":"Brito","year":"2017","journal-title":"Nephron"},{"key":"key20200713234411_b46-mmr-21-01-0393","doi-asserted-by":"publisher","first-page":"538","DOI":"10.1016\/j.bbrc.2018.09.018","article-title":"Indoxyl glucuronide, a protein-bound uremic toxin, inhibits hypoxia-inducible factor-dependent erythropoietin expression through activation of aryl hydrocarbon receptor","volume":"504","author":"Asai","year":"2018","journal-title":"Biochem Biophys Res Commun"},{"key":"key20200713234411_b47-mmr-21-01-0393","doi-asserted-by":"publisher","first-page":"960","DOI":"10.5551\/jat.34462","article-title":"Crucial role of the aryl hydrocarbon receptor (AhR) in indoxyl sulfate-induced vascular inflammation","volume":"23","author":"Ito","year":"2016","journal-title":"J Atheroscler Thromb"},{"key":"key20200713234411_b48-mmr-21-01-0393","doi-asserted-by":"publisher","first-page":"366","DOI":"10.2174\/1389450116666141230114500","article-title":"Indoxyl sulfate: A candidate target for the prevention and treatment of cardiovascular disease in chronic kidney disease","volume":"16","author":"Barisione","year":"2015","journal-title":"Curr Drug Targets"},{"key":"key20200713234411_b49-mmr-21-01-0393","doi-asserted-by":"publisher","first-page":"259","DOI":"10.1124\/pr.114.009001","article-title":"The aryl hydrocarbon receptor in barrier organ physiology, immunology, and toxicology","volume":"67","author":"Esser","year":"2015","journal-title":"Pharmacol Rev"},{"key":"key20200713234411_b50-mmr-21-01-0393","doi-asserted-by":"publisher","first-page":"282","DOI":"10.1007\/s12012-007-9007-6","article-title":"Crosstalk between the aryl hydrocarbon receptor and hypoxia on the constitutive expression of cytochrome P4501A1 mRNA","volume":"7","author":"Zhang","year":"2007","journal-title":"Cardiovasc Toxicol"},{"key":"key20200713234411_b51-mmr-21-01-0393","doi-asserted-by":"publisher","first-page":"483","DOI":"10.1053\/j.ajkd.2015.09.027","article-title":"Role of the gut microbiome in uremia: A potential therapeutic target","volume":"67","author":"Ramezan","year":"2016","journal-title":"Am J Kidney Dis"},{"key":"key20200713234411_b52-mmr-21-01-0393","doi-asserted-by":"publisher","first-page":"876","DOI":"10.1681\/ASN.2013121283","article-title":"The cardiovascular effect of the uremic solute indole-3 acetic acid","volume":"26","author":"Dou","year":"2015","journal-title":"J Am Soc Nephrol"},{"key":"key20200713234411_b53-mmr-21-01-0393","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1016\/j.taap.2005.07.005","article-title":"Characterizing the role of endothelin-1 in the progression of cardiac hypertrophy in aryl hydrocarbon receptor (AhR) null mice","volume":"212","author":"Lund","year":"2006","journal-title":"Toxicol Appl Pharmacol"},{"key":"key20200713234411_b54-mmr-21-01-0393","doi-asserted-by":"publisher","first-page":"605","DOI":"10.1177\/030098589703400609","article-title":"Lesions of aryl-hydrocarbon receptor-deficient mice","volume":"34","author":"Fernandez-Salguero","year":"1997","journal-title":"Vet Pathol"},{"key":"key20200713234411_b55-mmr-21-01-0393","doi-asserted-by":"publisher","first-page":"1334","DOI":"10.1289\/ehp.1307297","article-title":"Disruption of aryl hydrocarbon receptor homeostatic levels during embryonic stem cell differentiation alters expression of homeobox transcription factors that control cardiomyogenesis","volume":"121","author":"Wang","year":"2013","journal-title":"Environ Health Perspect"},{"key":"key20200713234411_b56-mmr-21-01-0393","doi-asserted-by":"publisher","first-page":"446","DOI":"10.1016\/j.pharmthera.2009.12.002","article-title":"Effect of cytochrome P450 polymorphism on arachidonic acid metabolism and their impact on cardiovascular diseases","volume":"125","author":"Zordoky","year":"2010","journal-title":"Pharmacol Ther"},{"key":"key20200713234411_b57-mmr-21-01-0393","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1016\/j.toxlet.2014.01.025","article-title":"Acute mercury toxicity modulates cytochrome P450, soluble epoxide hydrolase and their associated arachidonic acid metabolites in C57Bl\/6 mouse heart","volume":"226","author":"Amara","year":"2014","journal-title":"Toxicol Lett"},{"key":"key20200713234411_b58-mmr-21-01-0393","doi-asserted-by":"publisher","first-page":"512","DOI":"10.2174\/157016112800812746","article-title":"Cytochrome P450 1B1 and 2C9 genotypes and risk of ischemic vascular disease, cancer, and chronic obstructive pulmonary disease","volume":"10","author":"Kaur-Knudsen","year":"2012","journal-title":"Curr Vasc Pharmacol"},{"key":"key20200713234411_b59-mmr-21-01-0393","doi-asserted-by":"publisher","first-page":"456","DOI":"10.1016\/j.bcp.2013.11.015","article-title":"Alterations in cytochrome P450-derived arachidonic acid metabolism during pressure overload-induced cardiac hypertrophy","volume":"87","author":"El-Sherbeni","year":"2014","journal-title":"Biochem Pharmacol"},{"key":"key20200713234411_b60-mmr-21-01-0393","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1016\/j.prostaglandins.2011.12.003","article-title":"Contribution of cytochrome P450 1B1 to hypertension and associated pathophysiology: A novel target for antihypertensive agents","volume":"98","author":"Malik","year":"2012","journal-title":"Prostaglandins Other Lipid Mediat"},{"key":"key20200713234411_b61-mmr-21-01-0393","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1016\/j.lfs.2018.08.067","article-title":"Oxidative stress-chronic kidney disease-cardiovascular disease: A vicious circle","volume":"210","author":"Ravarotto","year":"2018","journal-title":"Life Sci"}],"container-title":["Molecular Medicine Reports"],"original-title":[],"deposited":{"date-parts":[[2020,7,14]],"date-time":"2020-07-14T00:39:21Z","timestamp":1594687161000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.spandidos-publications.com\/10.3892\/mmr.2019.10810"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,11,11]]},"references-count":61,"URL":"https:\/\/doi.org\/10.3892\/mmr.2019.10810","relation":{},"ISSN":["1791-2997","1791-3004"],"issn-type":[{"value":"1791-2997","type":"print"},{"value":"1791-3004","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,11,11]]}}}